Cathay Biotech is a global technology leader in synthetic biology and the use of bio-processes to produce new materials on an industrial scale. Cathay's long chain diacids are a perfect example demonstrating the potential for bio-manufacturing to commercially displace traditional chemical processes. Cathay also developed and became the first commercial producer of pentanediamine from renewable materials. Having the two key monomers to produce polyamides, Cathay also is a global innovator in the commercialization of new and unique renewable polyamides for the engineering polymer and textile markets. The series of bio-based polyamide products cover a wide range of new material with melting point from 130℃ to 315℃.
As a game-changing production technology, bio-production starts with biomass and other raw materials for biological conversion to higher value products. The nature of bio-production requires environmentally friendly and mild conditions that are inherently economical. The goal of Cathay's synthetic biology development programs is to address the excessive dependence of humans on traditionally produced chemicals as well as the subsequent environmental damage and worker safety issues associated with their production.
Cathay's headquarters and R&D are located at Zhangjiang Hi-Tech park in Shanghai and the two production sites are in Jinxiang and Wusu, P.R.China. The third production site is in construction process in Taiyuan, also in China, which will expand the capacity of current 75KT/a long chain diacids, 50KT/a pentanediamine and 100KT bio-based polyamides to much larger scale.
| Full name | Cathay Biotech Inc. |
|---|---|
| Abbreviations | Cathay Biotech |
| Code | 688065 |
| Founded | 2000-11-24 |
| Listing | 2020-08-12 |
| Domicile | Shanghai |
| cathaybiotech_info@cathaybiotech.com | |
| STAR Theme | New Materials |
| CSRC Sector | Bio-based Material Manufacture |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 1.18 | 1.32 | - |
| R&D expenditure as a % of operating revenue | 5.63% | 4.71% | 4.92% |
| Operating Revenue | 1,497.19 | 1,916.20 | 1,757.12 |
| Net Income | 457.67 | 478.88 | 466.29 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 1,497.19 | 1,916.20 | 1,757.12 |
| Operating Costs | 748.39 | 1,061.04 | 991.90 |
| Operating Income | 522.23 | 589.06 | 541.07 |
| Pretax Income | 520.79 | 555.87 | 541.03 |
| Income Tax | 63.45 | 76.99 | 74.74 |
| Net Income | 457.34 | 478.88 | 466.29 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 8,444.31 | 2,706.48 | 1,816.52 |
| Non-current Assets-Total | 3,690.84 | 3,275.30 | 3,023.10 |
| Total Assets | 12,135.15 | 5,981.78 | 4,839.63 |
| Liabilities | |||
| Current Liabilities-Total | 434.77 | 1,040.08 | 1,508.08 |
| Non-current Liabilities-Total | 215.97 | 299.84 | 174.81 |
| Total Liabilities | 650.74 | 1,339.92 | 1,682.88 |
| Stockholder's Equity | |||
| Share Capital | 9,098.13 | 3,817.66 | 2,737.71 |
| Retained Profits | 1,286.62 | 824.20 | 419.03 |
| Minority interests | 1,099.67 | - | - |
| Total Owners' Equity | 11,484.41 | 4,641.86 | 3,156.74 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 514.96 | 359.62 | -10.29 |
| Net Cash Flows-Investing | -1,197.23 | -1,206.72 | -587.60 |
| Net Cash Flows-Financing | 6,063.45 | 1,050.43 | 645.10 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| Cathay Industrial Biotech Ltd. | 118.00 | 28.32% |
| 山西科技创新城投资开发有限公司 | 38.07 |